Aventis Pharma Limited Sustainability Profile
Aventis Pharma Limited, a prominent player in the pharmaceutical industry, is headquartered in Great Britain and operates extensively across Europe and Asia. Founded in the early 2000s, the company has established itself as a leader in innovative healthcare solutions, focusing on prescription medicines and specialty pharmaceuticals. With a diverse portfolio that includes treatments for chronic diseases, oncology, and rare conditions, Aventis Pharma is recognised for its commitment to research and development. The company’s unique approach to drug formulation and patient care has positioned it as a trusted name in the market. Notable achievements include significant advancements in biopharmaceuticals and a strong emphasis on sustainability in its operations. Aventis Pharma Limited continues to strive for excellence, making a meaningful impact on global health.
DitchCarbon Score
How does Aventis Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aventis Pharma Limited's score of 62 is higher than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aventis Pharma Limited's reported carbon emissions
In 2024, Aventis Pharma Limited reported total carbon emissions of approximately 29,146,000 kg CO2e, with Scope 1 emissions at about 2,073,000 kg CO2e, Scope 2 emissions (location-based) at around 527,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled approximately 26,546,000 kg CO2e. This represents a decrease from 2023, where total emissions were about 32,400,000 kg CO2e, with Scope 1 at approximately 2,592,000 kg CO2e, Scope 2 at around 648,000 kg CO2e, and Scope 3 at about 29,160,000 kg CO2e. Aventis Pharma Limited's emissions data is cascaded from its parent company, Sanofi, reflecting a commitment to transparency and accountability in climate reporting. However, there are currently no specific reduction targets or initiatives disclosed under the Science Based Targets initiative (SBTi) or other climate pledges. The company is actively working within the framework established by Sanofi, which may include broader corporate sustainability goals. Overall, Aventis Pharma Limited is focused on understanding and managing its carbon footprint, with a clear emphasis on Scope 3 emissions, which constitute the majority of its total emissions.
How Carbon Intensive is Aventis Pharma Limited's Industry?
How Carbon Intensive is Aventis Pharma Limited's Location?
Aventis Pharma Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aventis Pharma Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
